SIMCERE PHARMA (02096) subsidiary has signed an exclusive licensing agreement with Ipsen for SIM0613 (LRRC15 antibody-conjugated drug).

SIMCERE PHARMA (02096) announced on December 19, 2025 that its subsidiary Jiangsu Shineagain Pharmaceutical Co., Ltd. (Jiangsu Shineagain) has signed an exclusive licensing agreement with Ipsen Pharma SAS. (Euronext stock code: IPN; ADR trading code: IPSEY) (Ipsen). According to the terms of the agreement, Ipsen will obtain the global exclusive development, production, and commercialization rights outside of Greater China for the antibody-drug conjugate (ADC) SIM0613, which targets LRRC15 and was developed by Jiangsu Shineagain. Under the agreement, the Group is entitled to receive payments of up to $1.06 billion, including a $45 million upfront payment, as well as milestone payments for research, regulatory, and commercialization, and royalties on tiered sales. SIM0613 is a novel ADC that targets LRRC15, a protein rich in leucine-rich repeat sequences. LRRC15 is highly expressed on the surface of various solid tumors and tumor-associated fibroblasts (CAF), but is minimally expressed in normal cells. After binding to LRRC15, SIM0613 enters tumor cells through endocytosis and releases a cytotoxic payload, effectively killing tumor cells while minimally affecting normal cells. Designed for deep penetration into tumors and tumor-associated fibroblasts, SIM0613 has demonstrated significant tumor regression effects in various preclinical models.